Tissue crosslinking for treatment of snoring and obstructive sleep apnea
A method of treating snoring and/or OSA in a subject in need of such treatment. The method includes crosslinking proteins of the subject's soft palate tissue or pharynx tissue. The crosslinking can occur by contacting the soft palate or pharynx tissue with a crosslinking reagent. In addition, the crosslinking can occur without heating, contracting or denaturing of the tissue, or any combination thereof.
1. A method of treating snoring and/or obstructive sleep apnea in a subject in need of such treatment, comprising decreasing oscillation magnitude and flaccidity of the subject's soft palate or pharynx tissue, when the tissue is subjected to physiologic airflow, by crosslinking tissue proteins within the tissue,
wherein the crosslinking comprises contacting the soft palate or pharynx tissue with a crosslinking reagent.
2. The method of claim 1 , wherein crosslinking occurs without heating, contracting, inducing fibrosis, or denaturing of the tissue, or any combination thereof.
3. The method of claim 1 , wherein the crosslinking reagent is delivered to the tissue via injection, spraying, a patch, a strip-type delivery device, or any combination thereof.
4. The method of claim 3 , wherein the injecting or spraying is of a liquid, emulsion or micro-emulsion.
5. The method of claim 3 , wherein the patch or delivery device is biodegradable or non-biodegradable.
6. The method of claim 5 , wherein the patch or delivery device is non-biodegradable and porous, and the crosslinker is embedded within the pores.
7. The method of claim 5 , wherein the patch is non-biodegradable and the crosslinker is adhered to one side of the patch as part of a semi-solid formulation.
8. The method of claim 5 , wherein the patch or delivery device is biodegradable and comprises a basic salt.
9. The method of claim 8 , wherein the salt is calcium carbonate, calcium hydroxyapatite, sodium bicarbonate, 2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).
10. The method of claim 5 , wherein the patch or delivery device is coated with one or more layers of crosslinker-containing biodegradable polymer.
11. The method of claim 10 , wherein each layer comprises a basic salt.
12. The method of claim 11 , wherein the salt is calcium carbonate, calcium hydroxyapatite, sodium bicarbonate, 2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).
13. The method of claim 10 , wherein the patch or delivery device is coated with multiple layers of crosslinker-containing biodegradable polymer, and the crosslinker varies from layer to layer.
14. The method of claim 5 , wherein the patch is affixed to the tissue with a bio-compatible adhesive.
15. The method of claim 14 , wherein the adhesive is poly(glycerol-co-sebacate acrylate), an oleic methyl ester or an alkyl ester cyanoacrylate.
16. The method of claim 1 , wherein the crosslinking reagent comprises one or more of the following crosslinkers: genipin, methylglyoxal, L-threose, D-threose, proanthocyanidin, EDC, or glutaraldehyde.
17. The method of claim 16 , wherein the crosslinker is genipin and wherein said genipin is at a concentration of about 10 to 60 mM in about 50 mM 4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) buffer at about pH 9 with about 50 mM phosphate ions.
18. The method of claim 16 , wherein the crosslinker is methylglyoxal and wherein said methylglyoxal is at a concentration of about 10-60 mM in about 50 mM 4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) buffer at about pH 9 with about 50 mM phosphate ions.